2025 Targeted Therapies of Lung Cancer (TTLC) - Posters-PP01.19 Real-World Outcomes with Tarlatamab in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer

PP01.19 Real-World Outcomes with Tarlatamab in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer

Back to course

Pdf Summary

The study examines the real-world safety of Tarlatamab, a recently approved CD3 DLL3 bispecific T-cell engager, for treating patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression following platinum-based chemotherapy and immunotherapy. Conducted between May and November 2024, the retrospective analysis reviewed data from patients treated at UAB and Infirmary Health System. The sample consisted of 14 patients, with a median age of 70 years, predominantly Caucasian, and mostly with a history of prior immunotherapy and chemotherapy treatments.<br /><br />Results highlighted the incidence and severity of adverse effects attributed to Tarlatamab. Over half of the patients (57%) experienced Cytokine Release Syndrome (CRS), predominantly grade 1 or 2 in severity, with a median onset time of 8 hours. Common CRS symptoms included tachycardia, tachypnea, and fever. Additionally, 28% of patients developed grade 2 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), with an onset median of 9.5 hours.<br /><br />Elevations in liver enzymes such as ALT and AST were noted, as well as thrombocytopenia, though grades for anemia, neutropenia, or pyrexia were not abnormally high. Patient-reported symptoms after the first dose frequently included fatigue, nausea, and vomiting.<br /><br />The study's insights suggest a higher occurrence of CRS and ICANS in real-world applications than in clinical trials and underscore the importance of further research into interventions to mitigate these adverse effects. The median hospitalization duration was 25.5 hours, and subsequent infusions posed less risk for severe CRS. Going forward, identifying risk factors and preventive strategies for toxicity remains a significant focus to enhance patient outcomes in this treatment area.

Asset Subtitle

Sameer Deshmukh

Keywords

Tarlatamab

CD3 DLL3 bispecific T-cell engager

extensive-stage small cell lung cancer

ES-SCLC

Cytokine Release Syndrome

CRS

Immune Effector Cell-Associated Neurotoxicity Syndrome

ICANS

adverse effects

real-world safety